Nightstar Therapeutics (NASDAQ:NITE)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $42.00 price target on the stock, up from their previous price target of $36.00. Cantor Fitzgerald’s price target suggests a potential upside of 215.79% from the stock’s current price.
NITE has been the subject of several other reports. Zacks Investment Research raised shares of Nightstar Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday. Leerink Swann boosted their price target on shares of Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a “positive” rating in a report on Monday, September 24th. UBS Group initiated coverage on shares of Nightstar Therapeutics in a report on Friday, January 4th. They set a “buy” rating and a $21.00 price target on the stock. Barclays initiated coverage on shares of Nightstar Therapeutics in a report on Monday, December 17th. They set an “overweight” rating and a $28.00 price target on the stock. Finally, Mizuho restated a “buy” rating and set a $24.00 price target on shares of Nightstar Therapeutics in a report on Tuesday, September 25th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $31.00.
NASDAQ NITE traded up $0.18 during mid-day trading on Thursday, reaching $13.30. 1,200 shares of the stock were exchanged, compared to its average volume of 68,583. Nightstar Therapeutics has a one year low of $9.59 and a one year high of $29.55. The company has a market capitalization of $358.27 million, a PE ratio of -8.22 and a beta of 3.34.
In other Nightstar Therapeutics news, insider Gregory Scott Robinson sold 14,764 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $11.15, for a total value of $164,618.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO David A. Fellows sold 8,733 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $12.98, for a total transaction of $113,354.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,328 shares of company stock worth $291,734.
A number of institutional investors have recently bought and sold shares of NITE. Bank of America Corp DE bought a new stake in Nightstar Therapeutics during the 2nd quarter worth approximately $132,000. Partner Fund Management L.P. increased its holdings in Nightstar Therapeutics by 0.7% during the 2nd quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock worth $16,272,000 after acquiring an additional 7,007 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $169,000. Janney Montgomery Scott LLC bought a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $204,000. Finally, JPMorgan Chase & Co. bought a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $214,000. 37.84% of the stock is currently owned by institutional investors and hedge funds.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Featured Article: What is Cost of Capital?
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.